Insights: News
As a diagnostics platform company that provides serious or complex laboratory testing, Mayo Clinic Laboratories is constantly working to advance patient care and broaden access to specialized testing. Learn about the latest news from Mayo Clinic Laboratories here, including new test launches, collaborations, operational updates, and more.
Most recent posts
Christopher Garcia, M.D., shares how secure digital tools, wearable data, and AI can enable more personalized diagnostic pathways, while still keeping clinicians in the driver’s seat.
The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.
The United States will observe the Thanksgiving holiday on Thursday, Nov. 23. On this day, Mayo Clinic Laboratories will be open; however, specimen shipments and deliveries to our laboratories will not be made by the carriers. To safeguard specimens, please follow these shipping recommendations.
Mayo Clinic launched an automated system called RENEW — reanalysis of negative whole-exome/genome data — in 2022 that tracks newly published discoveries of disease-causing genetic variants. Every three months, the system automatically uploads these new scientific findings from around the world, which are then compared to the Mayo Clinic Center for Individualized Medicine’s database of unsolved patient sequencing results. This comparison helps to identify potentially significant developments that could lead to a new diagnosis for a patient with a rare genetic disorder.
Join Mayo Clinic Laboratories at the National Society of Genetic Counselors (NSGC) Annual Conference. Our interactive booth will be staffed by genetic counselors who can discuss and answer questions about our genetic testing options.
Mayo Clinic Laboratories offers a ceremide test to advise patients and their clinicians of the potential risk of heart attack. Using liquid chromatography-mass spectrometry technology, the test renders an algorithmic score after sorting through molecular compounds of ceramides of cardiovascular interest. Ceramide testing can be used alongside traditional blood tests to investigate risk factors of coronary artery disease.
Mayo Clinic Laboratories is committed to security and to protecting your information. As part of this commitment, we will implement an optional two-step login process for Mayo Clinic Laboratories applications called Multi-Factor Authentication (MFA). This process is like the two-step login process used by many other apps and provides an extra layer of security.
Hurricane Lee will be impacting the New England area and northeastern Canada this weekend. We are monitoring and tracking the situation with our logistics partners to minimize challenges. Your organization will be contacted directly by the couriers if a route is modified or canceled due to the storm.
Hurricane Idalia is expected to impact Florida on Wednesday, Aug. 30. We are monitoring and tracking the situation with our logistics partners to minimize challenges.
Hurricane Hilary will be impacting the West Coast this weekend and into early next week. We are monitoring and tracking the situation with our logistics partners to minimize challenges. Clients will be contacted directly by the couriers if a route is modified or canceled due to the storm. Additionally, we are identifying and activating alternate solutions to help deliver client specimens to Mayo Clinic Laboratories.
Due to the Labor Day holiday (recognized on Monday, September 4th), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure specimen viability and avoid turnaround time delays, follow the guidelines below.
Mayo Clinic Laboratories’ MayoComplete Melanoma Panel is a comprehensive test that better informs the prognosis and treatment of melanoma. It can be applied to unusual tumors that haven’t yet been identified as melanoma as well as melanomas with complex molecular structures.
At Mayo Clinic, quality is not an act, it’s a habit. This commitment extends into BioPharma Diagnostics, where a team of four quality assurance assistants and three lab processing assistants has recently come together as the BioPharma Accessioning Pod. Their focus includes accommodating the unique requirements of BioPharma clinical trials and research samples during accessioning and sharing data and findings with the BioPharma Diagnostics team.